fludarabine has been researched along with etoposide in 79 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (10.13) | 18.2507 |
| 2000's | 34 (43.04) | 29.6817 |
| 2010's | 31 (39.24) | 24.3611 |
| 2020's | 6 (7.59) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Burckhardt, G; Flörl, S; Hagos, Y; Kühne, A; Marada, VV | 1 |
| Bosanquet, AG; Chapman, CS; Hutchinson, RM; Parker, AN | 1 |
| Calvert, L; Claxton, D; Durett, A; Giralt, S; Hamer, J; Kantarjian, H; Khouri, I; Liang, J; Talpaz, M; Tibbits, P | 1 |
| Bapat, A; Goldberg, J; Goldman, N; Gordon, R; Gryn, J | 1 |
| Curti, A; Lemoli, RM; Leopardi, G; Motta, MR; Rizzi, S; Testoni, N; Tura, S; Visani, G | 1 |
| Allen, PD; Kelsey, SM; Newland, AC; Richardson, DS | 2 |
| Cawley, JC; Clarke, AR; Griffiths, SD; Pettitt, AR | 1 |
| Bentley, P; Davies, S; Hidalgo de Quintana, J; Hoy, T; Pepper, C; Thomas, A | 1 |
| Akutsu, M; Bai, L; Furukawa, Y; Ichikawa, A; Kano, Y; Kon, K; Suzuki, K; Tsunoda, S | 1 |
| Carella, AM; Cavaliere, M; Corsetti, MT; De Stefano, F; Ferrara, R; Lambelet, P; Lerma, E; Loni, C; Pinotti, G; Romanelli, A; Tedeschi, L; Valbonesi, M; Verdiani, S; Vinci, M | 1 |
| Cordone, I; De Cuia, R; Fenu, S; Guerrisi, V; Mandelli, F; Mauro, FR; Meloni, G; Pescarmona, E; Proia, A; Reato, G | 1 |
| Kelleher, JF; King, AK; Konefal, S; Monteleone, PM; Steele, DA | 1 |
| Bonifazi, F; Bonini, A; Castellani, S; Gugliotta, L; Isidori, A; Lemoli, RM; Malagola, M; Martinelli, G; Motta, MR; Piccaluga, PP; Rizzi, S; Tura, S; Visani, G | 1 |
| Fezoui, H; Genet, P; Lionnet, F; Louvel, D; Pulik, M; Touahri, T | 1 |
| Döhner, H; Gabler, A; Haas, R; Hartmann, F; Hensel, M; Ho, AD; Jung, W; Schlenk, RF; Trümper, L; Weber-Nordt, R | 1 |
| Amir, G; Cohen, Y; Da'as, N; Gillis, S; Polliack, A; Rund, D | 1 |
| Cavenagh, J; Chopra, R; Clark, FJ; Culligan, D; Davies, A; Fuller, S; Hunt, L; Hunter, A; Littlewood, T; Lush, R; Marks, DI; Marsh, J; Milligan, DW; Parker, A; Schey, S; Smith, GM; Towlson, K; Vandenberghe, E; Williams, CD; Yin, J | 1 |
| Ayala, A; Cabanillas, F; Hagemeister, FB; Hess, M; Lee, MS; McLaughlin, P; Preti, A; Rodriguez, MA; Romaguera, J; Sarris, A; Smith, TL; Tsimberidou, AM; Yang, Y; Younes, A | 1 |
| Alinari, L; Baccarani, M; Stefoni, V; Tani, M; Zinzani, PL | 1 |
| Lucas, T; Samorapoompichit, P; Schedled, A; Sperr, WR; Steiner, M; Valent, P; Wachtler, F | 1 |
| Callea, V; Cutrona, G; Ferrarini, M; Ferraris, AM; Mangiola, M; Morabito, F; Oliva, BM; Rapezzi, D; Rossi, E; Spriano, M; Stelitano, C; Zupo, S | 1 |
| Fil'chenkov, AA; Nesina, IP; Smirnova, IA; Zavelevich, MP | 1 |
| Mikhailenko, VM; Philchenkov, AA; Zavelevich, MP | 1 |
| Barulli, S; D'Adamo, F; Guiducci, B; Isidori, A; Leopardi, G; Malagola, M; Malerba, L; Mele, A; Nicolini, G; Piccaluga, P; Politi, P; Sparaventi, G; Stramigioli, S; Talevi, N; Visani, G | 1 |
| Naito, K; Ohnishi, K | 1 |
| Behringer, D; Bertz, H; Finke, J; Küttler, T; Samek, E; Spyridonidis, A; Wäsch, R; Waterhouse, M | 1 |
| Avanzini, P; Baccarani, M; Bocchia, M; Bonini, A; Candoni, A; Castelli, M; Damiani, D; de Vivo, A; Fanin, R; Fiacchini, M; Gugliotta, L; Lauria, F; Malagola, M; Martinelli, G; Mazza, P; Michielutti, A; Ottaviani, E; Piccaluga, PP; Pricolo, G; Raspadori, D; Rondoni, M; Russo, D; Testoni, N; Visani, G; Zaccaria, A; Zuffa, E | 1 |
| Culligan, DJ; Johnston, PW; Milner, BJ; Mittal, S | 1 |
| Kotani, T; Nakamura, Y; Ueda, M; Yamaguchi, M | 1 |
| Cantu-Rodríguez, O; Gomez-Almaguer, D; Gonzalez-Llano, O; Gutierrez-Aguirre, H; Herrera-Garza, J; Jaime-Pérez, J; Mancias-Guerra, C | 1 |
| Anhalt, GJ; Cummins, DL; Meyerle, JH; Mimouni, D; Owens, N; Tzu, J | 1 |
| Arceci, RJ; Chen, AR; Colombani, P; Higman, MA; Schwartz, CL; Wharam, M; Williams, KM | 1 |
| Attarbaschi, A; Fritsch, G; Gadner, H; Lawitschka, A; Lion, T; Matthes-Martin, S; Minkov, M; Mittheisz, E; Steiner, M; Zoubek, A | 1 |
| Ades, L; Attal, M; Bernard, M; Blaise, D; Bordigoni, P; Bourhis, JH; Cassuto, JP; Chevalier, P; Deconinck, E; Facon, T; Garban, F; Ifrah, N; Kuentz, M; Lioure, B; Michallet, M; Milpied, N; Porcher, R; Renaud, M; Socié, G; Tabrizi, R; Tilly, H; Vernant, JP; Vigouroux, S | 1 |
| Atra, AA; Baothman, A; Elimam, NA; Kassar, A; Khattab, TM; Zayed, A | 1 |
| Gil, L; Komarnicki, M; Kozlowska-Skrzypczak, M; Mol, A; Poplawski, D; Styczynski, J | 1 |
| Kamijo, T; Koike, K; Nakazawa, Y; Sakashita, K; Shikama, N; Shiohara, M; Tanaka, M; Yanagisawa, R | 1 |
| Chew, E; Fairlie, WD; Grigg, AP; Huang, DC; Khaw, SL; Lee, EF; Mason, KD; Rayeroux, KC; Roberts, AW; Seymour, JF; Szer, J | 1 |
| Candoni, A; Fanin, R; Malagola, M; Russo, D; Simeone, E; Tiribelli, M | 1 |
| García-Sanz, R; González-López, TJ; Graciani, IF; Hermida, G; San Miguel, JF; Vázquez, L | 1 |
| Forman, SJ; Karanes, C; Kogut, N; Krishnan, AY; Nademanee, A; Nakamura, R; O'Donnell, M; Palmer, JM; Parker, P; Pullarkat, V; Rodriguez, R; Rosenthal, J; Senitzer, D; Shayani, S; Smith, E; Snyder, D | 1 |
| Celentano, M; Criscuolo, C; Ferrara, F; Izzo, T; Mele, G; Riccardi, C | 1 |
| Bishop, MR; Bryant, K; Dean, RM; Fowler, DH; Hakim, F; Jamshed, S; Neelapu, SS; Odom, J; Steinberg, SM | 1 |
| Chao, NJ; Chino, JP; Craciunescu, O; Folz, RJ; Horwitz, ME; Kelsey, CR; Marks, LB; Rizzieri, DA; Steffey, B | 1 |
| Bredeson, C; Ewell, M; Goodman, SA; Horowitz, MM; Kahl, BS; Laport, GG; Negrin, RS; Tomblyn, MR; Vose, JM | 1 |
| Ancliff, P; Darbyshire, P; Goulden, N; Green, N; Hancock, J; Leighton, C; Love, S; Masurekar, A; Moorman, AV; Morgan, M; Parker, C; Révész, T; Saha, V; Sutton, R; Waters, R | 1 |
| Choma, M; Chybicka, A; Cornish, J; Gorczyńska, E; Grund, G; Kowalczyk, JR; Peters, C; Sykora, KW; Wachowiak, J | 1 |
| Agha, M; Boyiadzis, M; Duggal, S; Foon, KA; Hou, JZ; Luong, TM; Mehta, DR; Raptis, A; Redner, RL; Schlesselman, JJ | 1 |
| Cassuto, JP; Cluzeau, T; De Matteis, M; Gratecos, N; Mannone, L; Mounier, N; Raynaud, S; Sirvent, A; Thyss, A; Ticchioni, M | 1 |
| Ashizawa, M; Kako, S; Kanda, Y; Kikuchi, M; Kimura, S; Nakasone, H; Nishida, J; Okuda, S; Oshima, K; Sakamoto, K; Sato, M; Terasako, K; Wada, H; Yamazaki, R | 1 |
| Bahlis, NJ; Carlson, L; Duan, Q; Duggan, P; Hasegawa, W; Russell, JA; Stewart, DA; Voralia, M | 1 |
| Acar, H; Aydemir, E; Bayrak, OF; Gulluoglu, S; Ozen, M; Sahin, F; Sevli, S; Yalvac, ME | 1 |
| Furuya, T; Ikeda, T; Inoue, M; Kaneda, H; Koshinaga, T; Maebayashi, T; Masuko, T; Mugishima, H; Ohashi, K; Sugito, K; Yagasaki, H | 1 |
| Bishop, MR; Bryant, K; Dean, RM; Dunleavy, K; Fowler, DH; Fry, TJ; Gress, RE; Hakim, F; Hughes, TE; Odom, J; Pavletic, SZ; Salit, RB; Steinberg, SM; Wilson, WH | 1 |
| Aurlien, E; Baggerød, E; Bishop, MR; Brinch, L; Dybedal, I; Egeland, T; Fløisand, Y; Fosså, A; Fowler, DH; Gedde-Dahl, T; Heldal, D; Holte, H; Kolstad, A; Kvalheim, G; Lauritzsen, GF; Lehne, G; Tjønnfjord, GE; Torfoss, D | 1 |
| Agha, M; Boyiadzis, M; Duggal, S; Hou, JZ; Im, A; Lin, Y; McLaughlin, B; Raptis, A; Redner, R; Smith, C | 1 |
| Albrecht, M; Bökkerink, J; Claviez, A; Dörffel, W; Holte, H; Karlen, J; Lüders, H; Mann, G; Marciniak, H; Niggli, F; Pötter, R; Rühl, U; Schellong, G; Schmiegelow, K; Schwarze, EW; Wickmann, L | 1 |
| Medeiros, BC | 1 |
| Aldoss, I; Haider, M; Ji, L; Pullarkat, V | 1 |
| Imamura, Y | 1 |
| Audisio, E; Boccadoro, M; Bruno, B; Crisà, E; Ferrero, D; Festuccia, M; Frairia, C; Gatti, T; Giai, V; Marmont, F; Passera, R; Riera, L | 1 |
| Forman, SJ; Kim, JH; Liu, A; Palmer, J; Rosenthal, J; Schultheiss, TE; Stein, A; Tsai, N; Wong, JY | 1 |
| Cortes, JE; Feldman, EJ; Goldberg, SL; Hogge, DE; Kantarjian, H; Kolitz, JE; Larson, M; Louie, AC; Pigneux, A; Recher, C; Rizzeri, DA; Schiller, G; Warzocha, K | 1 |
| Ahn, HS; Jang, IJ; Jang, MK; Kang, HJ; Kim, H; Kim, NH; Kim, S; Lee, JW; Lee, SH; Park, JD; Park, KD; Shin, HY; Song, SH; Yu, KS | 1 |
| Hasegawa, K; Hirayama, Y; Ishihara, T; Kanagawa, M; Koyama, J; Suzuki, T; Terui, T | 1 |
| Baba, J; Ichikawa, K; Igarashi, N; Ishikawa, D; Kagamu, H; Kondo, R; Koshio, J; Koya, T; Miura, S; Nakata, K; Narita, I; Nozaki, K; Okajima, M; Saida, Y; Sato, K; Shoji, S; Tanaka, J; Tanaka, T; Watanabe, S; Yoshizawa, H | 1 |
| Beyer, M; Dietrich, S; Göder, A; Heinzel, T; Kiweler, N; Krämer, OH; Linnebacher, M; Mahboobi, S; Mahendrarajah, N; Nikolova, T; Rauch, A; Reich, TR; Schäfer, C; Schneider, G; Sellmer, A; Sonnemann, J; Stojanovic, N; Tomicic, MT; Wieczorek, M | 1 |
| Bruno, B; Chalandon, Y; Charbonnier, A; Coiteux, V; Simon, N; Souchet, L; Taque, S; Vincent, L; Yakoub-Agha, I | 1 |
| Dührsen, U; Flasshove, M; Hanoun, M; Noppeney, R; Schmitz, C; Westhus, J | 1 |
| Cavo, M; Curti, A; Iannarone, C; Ocadlikova, D; Redavid, AR | 1 |
| Adachi, S; Goto, H; Hasegawa, D; Iwamoto, S; Kakuda, H; Koh, K; Miyamura, T; Moritake, H; Nakayama, H; Saito, A; Shiba, N; Shimada, A; Taga, T; Tanaka, S; Terui, K; Tomizawa, D; Yuza, Y | 1 |
| Aleinikova, O; Ansari, M; Ariffin, H; Bader, P; Balduzzi, A; Bierings, M; Buechner, J; Burkhardt, B; Corbacioglu, S; Dalle, JH; Diaz-de-Heredia, C; Essa, M; Güngör, T; Ifversen, M; Lankester, A; Locatelli, F; Meisel, R; Peters, C; Pichler, H; Poetschger, U; Schrappe, M; Schultz, K; Sedlacek, P; Shaw, PJ; Staciuk, R; Stein, J; Svec, P; Toporski, J; Truong, TH; Vettenranta, K; von Stackelberg, A | 1 |
| Bas, EG; Celen, S; Daloglu, H; Hazar, V; Kabakci, C; Karasu, GT; Pashayev, D; Pehlivan, B; Uygun, V; Yalcin, K; Yesilipek, A; Zhumatayev, S | 1 |
| Akiyama, M; Goto, H; Hasegawa, D; Honda, T; Kumamoto, T; Ogawa, S; Takagi, M; Terao, YM; Yamaoka, M; Yoshida, K | 1 |
4 review(s) available for fludarabine and etoposide
| Article | Year |
|---|---|
Bilateral breast relapse in acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantation; Breast; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Graft vs Host Disease; Humans; Idarubicin; Immunologic Factors; Interleukin-2; Leukemia, Myeloid, Acute; Leukemic Infiltration; Radiotherapy, High-Energy; Recurrence; Salvage Therapy; Thioguanine; Transplantation Conditioning; Vidarabine | 2001 |
[Current and new therapeutic strategies in acute myeloid leukemia].
Topics: Acute Disease; Aminoglycosides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Cytarabine; Disease-Free Survival; Etoposide; fms-Like Tyrosine Kinase 3; Furans; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Indoles; Leukemia, Myeloid; Mice; Middle Aged; Mitoxantrone; Piperazines; Prognosis; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases; Vidarabine | 2005 |
[Hemophagocytic lymphohistiocytosis].
Topics: Antibodies, Monoclonal, Murine-Derived; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; Disease Progression; Doxorubicin; Drug Therapy, Combination; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphohistiocytosis, Hemophagocytic; Methotrexate; Multiple Organ Failure; Prednisolone; Prednisone; Rituximab; Severity of Illness Index; Transplantation Conditioning; Vidarabine; Vincristine | 2014 |
[Dose adaptation of the drugs used for hematopoietic stem-cell transplantation in patients with comorbidity: Obesity, chronic renal disease or hepatopathy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-T
Topics: Adult; Age Factors; Busulfan; Child; Comorbidity; Cyclophosphamide; Etoposide; France; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Liver Diseases; Melphalan; Obesity; Renal Insufficiency, Chronic; Societies, Medical; Surveys and Questionnaires; Thiotepa; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2017 |
18 trial(s) available for fludarabine and etoposide
| Article | Year |
|---|---|
Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cyclosporine; Cytarabine; Etoposide; Female; Graft vs Tumor Effect; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Pilot Projects; Risk Factors; Survival Rate; Transplantation Chimera; Vidarabine | 2000 |
Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Mitoxantrone; Remission Induction; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2001 |
Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.
Topics: Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2002 |
Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Bleomycin; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Prednisone; Procarbazine; Prognosis; Remission Induction; Survival Rate; Vidarabine; Vincristine | 2002 |
Mini-ICE effectively mobilises peripheral blood stem cells after fludarabine-based regimens in acute myeloid leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukapheresis; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Vidarabine | 2005 |
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Prospective Studies; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2005 |
FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Remission Induction; Vidarabine; Young Adult | 2009 |
A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.
Topics: Adolescent; Adult; Busulfan; Child; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Pilot Projects; Radiation Dosage; Siblings; Sirolimus; Survival Analysis; Tacrolimus; Thrombotic Microangiopathies; Tissue Donors; Transplantation Conditioning; Vidarabine; Young Adult | 2010 |
Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Living Donors; Lymphoma, Follicular; Male; Methotrexate; Middle Aged; Remission Induction; Rituximab; Salvage Therapy; Siblings; Tacrolimus; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2011 |
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Etoposide; Female; Humans; Idarubicin; Infant; Kaplan-Meier Estimate; Leukocyte Count; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Polyethylene Glycols; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Assessment; Treatment Outcome; United Kingdom; Vidarabine; Vincristine | 2010 |
Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematologic Neoplasms; Humans; Infant; Male; Melphalan; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
A prospective phase II study of RICE re-induction, then high-dose fludarabine and busulfan, followed by autologous or allogeneic blood stem cell transplantation for indolent b-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Prospective Studies; Quality of Life; Rituximab; Survival Rate; Transplantation Conditioning; Vidarabine | 2011 |
Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Rituximab; Sirolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Vincristine; Young Adult | 2012 |
Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cytarabine; Etoposide; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Recurrence; Remission Induction; Salvage Therapy; Vidarabine | 2012 |
Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Proportional Hazards Models; Remission Induction; Risk; Survival Analysis; Topotecan; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2014 |
Extramedullary relapse following total marrow and lymphoid irradiation in patients undergoing allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Blast Crisis; Bone Marrow; Busulfan; Child; Cyclophosphamide; Etoposide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphatic Irradiation; Melphalan; Middle Aged; Myelodysplastic Syndromes; Organ Sparing Treatments; Organs at Risk; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Radiotherapy Dosage; Recurrence; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2014 |
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
Topics: Adult; Aged; Aminoglycosides; Amsacrine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Humans; Injections; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Risk Assessment; Salvage Therapy; Treatment Outcome; Vidarabine | 2015 |
Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemoradiotherapy; Child; Child, Preschool; Equivalence Trials as Topic; Etoposide; Female; Follow-Up Studies; Humans; International Agencies; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Survival Rate; Thiotepa; Vidarabine; Whole-Body Irradiation | 2021 |
57 other study(ies) available for fludarabine and etoposide
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Humans; Liver-Specific Organic Anion Transporter 1; Molecular Structure; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Peptides; Solute Carrier Organic Anion Transporter Family Member 1B3 | 2015 |
Effective treatment of relapsed acute myeloid leukaemia with drugs chosen by DiSC assay.
Topics: Acute Disease; Antineoplastic Agents; Cytotoxicity Tests, Immunologic; Drug Hypersensitivity; Etoposide; Female; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Recurrence; Vidarabine | 1992 |
Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autolog
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Cell Survival; Colony-Forming Units Assay; Combined Modality Therapy; Cyclophosphamide; Daunorubicin; Diploidy; Etoposide; Female; Genetic Markers; Hematopoietic Stem Cells; Humans; Idarubicin; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mitoxantrone; Neoplastic Stem Cells; Philadelphia Chromosome; Remission Induction; Survival Rate; Vidarabine; Whole-Body Irradiation | 1995 |
Pentostatin increases the acute toxicity of high dose cyclophosphamide.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Synergism; Etoposide; Fatal Outcome; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Pentostatin; Prednisone; Rats; Rats, Inbred Lew; Salvage Therapy; Shock, Cardiogenic; Ventricular Fibrillation; Vidarabine; Vincristine | 1993 |
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Bone Marrow Purging; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Length of Stay; Leukemia, Myeloid; Male; Mechlorethamine; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Neoplastic Stem Cells; Pilot Projects; Platelet Transfusion; Recurrence; Remission Induction; Risk; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine | 1999 |
Inhibition of FAS/FAS-ligand does not block chemotherapy-induced apoptosis in drug sensitive and resistant cells.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Cell Cycle; Clone Cells; Drug Resistance, Multiple; Etoposide; Fas Ligand Protein; fas Receptor; HL-60 Cells; Humans; Idarubicin; Leukemia-Lymphoma, Adult T-Cell; Membrane Glycoproteins; Tumor Cells, Cultured; Vidarabine; Vinblastine | 1999 |
Effects of PARP inhibition on drug and Fas-induced apoptosis in leukaemic cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Drug Resistance, Multiple; Enzyme Inhibitors; Etoposide; fas Receptor; Genes, MDR; HL-60 Cells; Humans; Idarubicin; Leukemia-Lymphoma, Adult T-Cell; Microtubules; Phenanthrenes; Poly(ADP-ribose) Polymerase Inhibitors; Tumor Cells, Cultured; Vidarabine; Vinblastine | 1999 |
Purine analogues kill resting lymphocytes by p53-dependent and -independent mechanisms.
Topics: Animals; Cell Death; Cladribine; Coformycin; Dexamethasone; Drug Resistance; Etoposide; Genes, p53; Lymphocytes; Mice; Mice, Knockout; Spleen; Vidarabine | 1999 |
Pleiotropic drug resistance in B-cell chronic lymphocytic leukaemia--the role of Bcl-2 family dysregulation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Chlorambucil; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 1999 |
In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Survival; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Humans; Hydroxyurea; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Methotrexate; Neoplastic Stem Cells; Tumor Cells, Cultured; Vidarabine; Vidarabine Phosphate; Vincristine | 2000 |
Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem-cell transplantation.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Fatal Outcome; Genetic Predisposition to Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lung Neoplasms; Male; Middle Aged; Neoplasm, Residual; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Recombinant Proteins; Risk; Smoking; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2000 |
Toxoplasmic encephalitis in a non-HIV patient with follicular lymphoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Female; Humans; Immunocompromised Host; Interferon-alpha; Lymphoma, Follicular; Opportunistic Infections; Prednisone; Salvage Therapy; Teniposide; Toxoplasmosis, Cerebral; Vidarabine | 2002 |
Acute myocardial infarction as the presenting symptom of acute myeloblastic leukemia with extreme hyperleukocytosis.
Topics: Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Confusion; Cytarabine; Etoposide; Fatal Outcome; Female; Gemtuzumab; Humans; Idarubicin; Immunotherapy; Leukapheresis; Leukemia, Myeloid, Acute; Leukocytosis; Middle Aged; Mitoxantrone; Myocardial Infarction; Recurrence; Remission Induction; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3; Therapeutics; Vidarabine | 2002 |
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclosporine; Cytarabine; Data Collection; Etoposide; Female; Follow-Up Studies; Graft Enhancement, Immunologic; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Waldenstrom's macroglobulinemia: is there a place and time for a cease-fire?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Case Management; Chlorambucil; Cladribine; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Immunoglobulin M; Male; Middle Aged; Mitoxantrone; Plasmapheresis; Prednisone; Rituximab; Severity of Illness Index; Thalidomide; Vidarabine; Vinblastine; Vincristine; Vinorelbine; Waldenstrom Macroglobulinemia | 2003 |
Induction of apoptosis in the human mast cell leukemia cell line HMC-1 by various antineoplastic drugs.
Topics: 2-Chloroadenosine; Antineoplastic Agents; Apoptosis; Cisplatin; Cytarabine; Deoxyadenosines; DNA Fragmentation; Doxorubicin; Endodeoxyribonucleases; Etoposide; Humans; In Situ Nick-End Labeling; Leukemia, Mast-Cell; Microscopy, Electron; Neoplasm Proteins; Tumor Cells, Cultured; Vidarabine; Vincristine | 2003 |
Expression of CD10 by B-chronic lymphocytic leukemia cells undergoing apoptosis in vivo and in vitro.
Topics: ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Amino Acid Chloromethyl Ketones; Antibodies; Antibodies, Monoclonal; Antigens, CD; Apoptosis; B-Lymphocytes; Cell Line, Tumor; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Immunoglobulin A; Immunoglobulin D; Immunoglobulin M; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Glycoproteins; Neprilysin; Palatine Tonsil; Vidarabine | 2003 |
Effects of etoposide and fludarabine in subtoxic doses on karyotype of human malignant lymphoid Namalwa cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Chromatids; Chromosome Aberrations; Chromosomes; Culture Media; DNA Damage; Dose-Response Relationship, Drug; Etoposide; Humans; Karyotyping; Lymphoma; Mutagens; Vidarabine | 2003 |
Analysis of 1H NMR-detectable mobile lipid domains for assessment of apoptosis induced by inhibitors of DNA synthesis and replication.
Topics: Apoptosis; Cell Line, Tumor; Cell Membrane; DNA Replication; Etoposide; Humans; Hydrogen; Magnetic Resonance Spectroscopy; Membrane Lipids; Quercetin; Vidarabine | 2005 |
Reduced intensity conditioning compared to standard conditioning preserves the in vitro growth capacity of bone marrow stroma, which remains of host origin.
Topics: Adult; Aged; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Bone Marrow Transplantation; Busulfan; Cell Culture Techniques; Cell Proliferation; Cell Transplantation; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cells; Humans; Immunohistochemistry; Immunosuppressive Agents; In Situ Hybridization, Fluorescence; Lewis X Antigen; Lipopolysaccharide Receptors; Lymphoma; Male; Microscopy, Fluorescence; Middle Aged; Myelodysplastic Syndromes; Nucleic Acid Synthesis Inhibitors; Stromal Cells; Transplantation Conditioning; Vidarabine | 2005 |
A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Crohn Disease; Cytarabine; Epirubicin; Epstein-Barr Virus Infections; Etoposide; Fatal Outcome; Gene Rearrangement, delta-Chain T-Cell Antigen Receptor; Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunosuppressive Agents; Liver; Lymphoma, T-Cell, Peripheral; Lymphoproliferative Disorders; Male; Methylprednisolone; Pentostatin; Receptors, Antigen, T-Cell, gamma-delta; Remission Induction; Spleen; Transplantation, Homologous; Vidarabine | 2006 |
Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Male; Methylprednisolone; Neoplasms, Second Primary; Prednisone; Recurrence; Remission Induction; Time Factors; Vidarabine; Vincristine | 2006 |
Successful father-to-son stem cell transplantation in a child with hemophagocytic lymphohistiocytosis using a reduced-intensity conditioning regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Etoposide; Family; Graft vs Host Disease; Humans; Infant; Lymphohistiocytosis, Hemophagocytic; Magnetic Resonance Imaging; Male; Melphalan; Methotrexate; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine | 2006 |
Lichenoid paraneoplastic pemphigus in the absence of detectable antibodies.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; B-Lymphocytes; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Esophageal Diseases; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunity, Cellular; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Lichenoid Eruptions; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mucositis; Paraneoplastic Syndromes; Pemphigus; Prednisone; Recurrence; Rituximab; T-Lymphocytes; Vidarabine; Vincristine | 2007 |
Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biliary Atresia; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunocompromised Host; Immunosuppressive Agents; Liver Transplantation; Lymphoma, T-Cell, Peripheral; Lymphoproliferative Disorders; Melphalan; Mesna; Postoperative Complications; Prednisone; Radiotherapy, Adjuvant; Transplantation, Autologous; Vidarabine; Vincristine | 2008 |
Importance of allogeneic T-cells for disease control after stem cell transplantation for high-risk Langerhans cell histiocytosis.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Bone Marrow Transplantation; Combined Modality Therapy; Drug Therapy, Combination; Etoposide; Female; Graft Survival; Histiocytosis, Langerhans-Cell; Humans; Infant; Lymphocyte Transfusion; Lymphohistiocytosis, Hemophagocytic; Melphalan; Prednisone; Remission Induction; T-Lymphocyte Subsets; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Vinblastine | 2007 |
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
Topics: Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Data Collection; Disease-Free Survival; Etoposide; Female; France; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2007 |
Improved outcome of children with acute myeloid leukemia treated on 2 consecutive protocols.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Retrospective Studies; Saudi Arabia; Survival Rate; Treatment Outcome; Vidarabine | 2008 |
Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Carmustine; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Lymphoproliferative Disorders; Male; Melphalan; Middle Aged; Neutropenia; Prospective Studies; Risk Factors; Rituximab; Vidarabine; Young Adult | 2009 |
Low toxicity of a conditioning with 8-Gy total body irradiation, fludarabine and cyclophosphamide as preparative regimen for allogeneic hematopoietic stem cell transplantation in pediatric hematological malignancies.
Topics: Adolescent; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Infant; Leukemia; Male; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2009 |
The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; bcl-X Protein; Biphenyl Compounds; Dexamethasone; Doxorubicin; Drug Synergism; Etoposide; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Mimicry; Nitrophenols; Piperazines; Prognosis; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Vidarabine | 2009 |
The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Organoplatinum Compounds; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Topotecan; Transplantation, Autologous; Vidarabine; Vinblastine; Vincristine | 2010 |
Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Chromosome Aberrations; Cytarabine; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Remission Induction; Retrospective Studies; Survival Rate; Time Factors; Transplantation, Homologous; Vidarabine; Young Adult | 2010 |
EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Prednisone; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Vincristine | 2011 |
Severe pulmonary toxicity after myeloablative conditioning using total body irradiation: an assessment of risk factors.
Topics: Acute Disease; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Lung; Male; Melphalan; Middle Aged; Pneumonia; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2011 |
Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2011 |
New sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem-cell transplantation in very high-risk acute myeloid leukemia.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Thiotepa; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
FAME, a novel conditioning regimen for allogeneic stem cell transplantation for lymphoma, does not earn fame.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
The effects of chemotherapeutic agents on differentiated chordoma cells.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzamides; Bone Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Lineage; Chordoma; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Imatinib Mesylate; Methotrexate; Piperazines; Pyrimidines; Vidarabine; Vincristine | 2011 |
Application of high-dose rate (60)Co remote after-loading system for local recurrent neuroblastoma.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Busulfan; Carboplatin; Cisplatin; Cobalt Radioisotopes; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; Male; Melphalan; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neuroblastoma; Peripheral Blood Stem Cell Transplantation; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Vidarabine; Vincristine | 2011 |
Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Interleukin-15; Interleukin-7; Lymphocyte Depletion; Lymphoma; Male; Middle Aged; Prednisone; Rituximab; Salvage Therapy; Treatment Outcome; Vidarabine; Vincristine | 2012 |
Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Child; Child, Preschool; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; International Agencies; Male; Neoplasm Grading; Neoplasm Staging; Prednisone; Procarbazine; Prognosis; Remission Induction; Survival Rate; Vidarabine; Vincristine | 2013 |
Facts about FCE (fludarabine, cytarabine, etoposide) in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Salvage Therapy; Vidarabine | 2014 |
The combination of fludarabine, cytarabine and etoposide is an active and well-tolerated regimen in relapsed/refractory acute myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Salvage Therapy; Secondary Prevention; Survival Analysis; Vidarabine | 2014 |
Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients.
Topics: Child; Child, Preschool; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Injections, Intravenous; Male; Myeloablative Agonists; Neutrophils; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine; Young Adult | 2015 |
B-cell lymphoma developing de novo hepatitis B after salvage therapies including rituximab through seroconversion of surface antibody.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Lymphoma, B-Cell; Prednisone; Recurrence; Remission Induction; Risk; Rituximab; Salvage Therapy; Vidarabine; Vincristine; Virus Activation | 2014 |
Critical Roles of Chemoresistant Effector and Regulatory T Cells in Antitumor Immunity after Lymphodepleting Chemotherapy.
Topics: Adoptive Transfer; Animals; Cisplatin; Cyclophosphamide; Cytotoxins; Deoxycytidine; Drug Resistance; Etoposide; Female; Fibrosarcoma; Gemcitabine; Lymph Nodes; Lymphocyte Depletion; Lymphopenia; Methylcholanthrene; Mice; Mice, Inbred C57BL; Mice, Knockout; Paclitaxel; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Tumor Cells, Cultured; Vidarabine; Whole-Body Irradiation | 2015 |
Class I histone deacetylases regulate p53/NF-κB crosstalk in cancer cells.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cellular Senescence; DNA Damage; DNA, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxyurea; Models, Biological; Mutation; Neoplasms; NF-kappa B; Signal Transduction; Tumor Suppressor Protein p53; Vidarabine | 2017 |
Etoposide Combined with FLAG Salvage Therapy Is Effective in Multiple Relapsed/Refractory Acute Myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hemorrhage; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Vidarabine | 2020 |
A Screening of Antineoplastic Drugs for Acute Myeloid Leukemia Reveals Contrasting Immunogenic Effects of Etoposide and Fludarabine.
Topics: Adenosine Triphosphate; Alarmins; Antineoplastic Agents; Calreticulin; Cell Line, Tumor; Cytarabine; Daunorubicin; Dendritic Cells; Etoposide; Extracellular Space; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Immunogenic Cell Death; Leukemia, Myeloid, Acute; Lymphocyte Activation; Neoplasm Proteins; Organelles; Protein Transport; T-Lymphocyte Subsets; Vidarabine | 2020 |
The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study.
Topics: Adolescent; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Rate; Transplantation, Homologous; Vidarabine | 2021 |
Comparison of Total Body Irradiation-based Versus Chemotherapy-based Conditionings for Early Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Children With ALL.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Organophosphorus Compounds; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2021 |
Successful treatment of hepatosplenic T-cell lymphoma with fludarabine, high-dose cytarabine and subsequent unrelated umbilical cord blood transplantation.
Topics: Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclin-Dependent Kinase Inhibitor p16; Cyclophosphamide; Cytarabine; DNA-Binding Proteins; Etoposide; ETS Translocation Variant 6 Protein; Female; Gene Deletion; Humans; Liver Neoplasms; Lymphoma, T-Cell; PAX5 Transcription Factor; Prognosis; Proto-Oncogene Proteins c-ets; Remission Induction; Repressor Proteins; Splenic Neoplasms; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2022 |